1. Home
  2. MLYS vs ENS Comparison

MLYS vs ENS Comparison

Compare MLYS & ENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • ENS
  • Stock Information
  • Founded
  • MLYS 2019
  • ENS 1991
  • Country
  • MLYS United States
  • ENS United States
  • Employees
  • MLYS N/A
  • ENS N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • ENS Industrial Machinery/Components
  • Sector
  • MLYS Health Care
  • ENS Technology
  • Exchange
  • MLYS Nasdaq
  • ENS Nasdaq
  • Market Cap
  • MLYS 3.1B
  • ENS 3.4B
  • IPO Year
  • MLYS 2023
  • ENS N/A
  • Fundamental
  • Price
  • MLYS $40.00
  • ENS $121.72
  • Analyst Decision
  • MLYS Strong Buy
  • ENS Strong Buy
  • Analyst Count
  • MLYS 6
  • ENS 2
  • Target Price
  • MLYS $42.60
  • ENS $117.50
  • AVG Volume (30 Days)
  • MLYS 1.3M
  • ENS 366.7K
  • Earning Date
  • MLYS 11-10-2025
  • ENS 11-05-2025
  • Dividend Yield
  • MLYS N/A
  • ENS 0.86%
  • EPS Growth
  • MLYS N/A
  • ENS 32.64
  • EPS
  • MLYS N/A
  • ENS 8.77
  • Revenue
  • MLYS N/A
  • ENS $3,657,687,000.00
  • Revenue This Year
  • MLYS N/A
  • ENS $2.83
  • Revenue Next Year
  • MLYS N/A
  • ENS $3.01
  • P/E Ratio
  • MLYS N/A
  • ENS $13.85
  • Revenue Growth
  • MLYS N/A
  • ENS 3.73
  • 52 Week Low
  • MLYS $8.24
  • ENS $76.57
  • 52 Week High
  • MLYS $44.80
  • ENS $124.84
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 53.93
  • ENS 61.57
  • Support Level
  • MLYS $41.74
  • ENS $116.87
  • Resistance Level
  • MLYS $44.60
  • ENS $124.47
  • Average True Range (ATR)
  • MLYS 2.22
  • ENS 3.93
  • MACD
  • MLYS -0.83
  • ENS -0.02
  • Stochastic Oscillator
  • MLYS 46.44
  • ENS 80.45

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About ENS EnerSys

EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.

Share on Social Networks: